多参数MRI时代初始省略活检后临床显著性前列腺癌的检出
本研究纳入2018年3月至2021年6月PSA 2-20 ng/mL、初始多参数前列腺MRI为PIRADS 1-3且未选择活检的活检初治男性,分析重复MRI、后续活检及临床显著性前列腺癌(csPCa,Grade Group ≥2)检出的相关因素。1494例中31%(463/1494)未行活检,csPCa无诊断生存率为97.6%(326/334),中位随访23.1个月,后续csPCa检出率为2.4%。
要点
- PSA密度≤0.1、前列腺健康指数(PHI)<55及PIRADS 1-2与省略前列腺活检相关。
- 未活检者csPCa无诊断生存率为97.6%(326/334),中位随访23.1个月(IQR 15.1-34.6个月)。
- 后续确诊csPCa的8例在重复mpMRI时均为PIRADS 4-5。
核心结论
- 初始mpMRI后未行活检的患者后续csPCa检出率低,为2.4%。
- 在初始PHI、PSAD和mpMRI令人放心的情况下省略活检,结合随访中令人放心的血清生物标志物和针对性mpMRI,似乎是安全的。
研究设计与样本
- 研究为对活检初治男性的分析,纳入PSA 2-20 ng/mL、2018年3月至2021年6月行初始mpMRI为PIRADS 1-3、未选择活检且随访≥6个月的男性。
- 采用单变量和多变量logistic回归分析与重复mpMRI、进展至活检及后续csPCa检出相关的因素。
主要发现
- 1494例男性中31%(463/1494)未行前列腺活检。
- PSA密度≤0.1、PHI<55和PIRADS 1-2与省略前列腺活检相关。
- csPCa无诊断生存率为97.6%(326/334),中位随访23.1个月(IQR 15.1-34.6个月)。
- 黑人种族、PSA、PHI、PSA密度及PSA和PHI速度是接受重复mpMRI(15.6%,52/334)和后续活检(8.4%,28/334)的显著预测因素。
- 8例随后诊断为csPCa(7例经前列腺活检,1例经钬激光前列腺剜除术偶然发现)。
关键数值与推荐
- 后续csPCa检出率为2.4%。
- 所有确诊csPCa的患者在重复mpMRI时均为PIRADS 4-5。
临床怎么用
- 作者认为,在初始PHI、PSAD和mpMRI令人放心的情况下省略活检,并结合随访中令人放心的血清生物标志物和针对性mpMRI,似乎是安全的。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric prostate MRI (mpMRI) is being increasingly adopted for work-up of prostate cancer. For patients selected to omit biopsy, we identified factors associated with repeat MRI, eventual prostate biopsy, and subsequent detection of clinically significant prostate cancer (csPCa, Grade Group ≥2). METHODS: We identified biopsy-naïve men presenting with PSA 2-20 ng/mL (March 2018-June 2021) undergoing initial mpMRI with PIRADS 1-3 lesions who were not selected for biopsy with ≥6 months follow-up. We examined factors associated with repeat mpMRI, progression to biopsy, and subsequent detection of csPCa with univariable and multivariable logistic regression. RESULTS: Of 1494 men, 31% (463/1494) did not pursue biopsy. PSA density (PSAD) ≤ 0.1, prostate health index (PHI) < 55, and PIRADS 1-2 were associated with omission of prostate biopsy. csPCa diagnosis-free survival was 97.6% (326/334) with median follow up of 23.1 months (IQR 15.1-34.6 months). Black race, PSA, PHI, PSA density, and PSA and PHI velocity were significant predictors of undergoing repeat mpMRI (15.6%, 52/334) and subsequent biopsy (8.4%, 28/334). 8 men were subsequently diagnosed with csPCa (N = 7 on prostate biopsy; N = 1 incidentally on holmium enucleation of prostate). All patients diagnosed with csPCa had PIRADS 4-5 on repeat mpMRI. CONCLUSIONS: The subsequent detection rate of csPCa among patients not initially biopsied after mpMRI was low at 2.4%. Decisions to omit biopsy after initial reassuring PHI, PSAD, and mpMRI appear safe with subsequent reassuring serum biomarkers and for cause mpMRI during follow-up.
引用
- Li EV, Busza AM, Siddiqui MR, et al. Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era. Prostate Cancer Prostatic Dis. 2024. PMID: 38858446. doi:10.1038/s41391-024-00853-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。